Peer-reviewed veterinary case report
Radiation and toceranib treatment for dog mast cell tumors
By Carlsten, K S et al.·Published in Journal of veterinary internal medicine·2012·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
- Species:
- dog
Plain-English summary
A group of 17 dogs with measurable mast cell tumors (a type of skin tumor) that couldn't be surgically removed were treated with a combination of toceranib (a cancer medication), prednisone (a steroid), and hypofractionated radiation therapy. Most dogs responded well to the treatment, with 76.4% showing improvement—nearly 59% had complete tumor shrinkage. The treatment was generally well tolerated, although some dogs experienced mild gastrointestinal and liver side effects. This combination therapy proved to be a promising option for dogs with these challenging tumors.
People also search for: dog mast cell tumor treatment · toceranib side effects in dogs · radiation therapy for dog tumors
Abstract
BACKGROUND: Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed. HYPOTHESIS: The combination of toceranib, prednisone, and hypofractionated radiation treatment (RT) will be well tolerated and efficacious. ANIMALS: Seventeen client-owned dogs with measurable MCT amenable to RT. METHODS: Prospective clinical trial. All dogs received prednisone, omeprazole, diphenhydramine, and toceranib. Toceranib was administered for 1 week before initiating RT, consisting of 24 Gy delivered in 3 or 4 fractions. RESULTS: On an intent-to-treat basis, the overall response rate was 76.4%, with 58.8% of dogs achieving a complete response and 17.6% a partial response. The median time to best response was 32 days, and the median progression-free interval was 316 days. The overall median survival time was not reached with a median follow-up of 374 days. The most common toxicoses were gastrointestinal and hepatic. CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of hypofractionated RT, toceranib, and prednisone was tolerated and efficacious in the majority of dogs. Response rates and durations were higher than those reported for toceranib as a single-agent treatment for MCT. This combination is a viable treatment option for unresectable MCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22176473/